Cancer cells adapt their metabolic processes to drive macromolecular biosynthesis for rapid cell growth and proliferation 1, 2 . RNA interference (RNAi)-based loss-of-function screening has proven powerful for the identification of new and interesting cancer targets, and recent studies have used this technology in vivo to identify novel tumour suppressor genes 3 . Here we developed a method for identifying novel cancer targets via negative-selection RNAi screening using a human breast cancer xenograft model at an orthotopic site in the mouse. Using this method, we screened a set of metabolic genes associated with aggressive breast cancer and stemness to identify those required for in vivo tumorigenesis. Among the genes identified, phosphoglycerate dehydrogenase (PHGDH) is in a genomic region of recurrent copy number gain in breast cancer and PHGDH protein levels are elevated in 70% of oestrogen receptor (ER)-negative breast cancers. PHGDH catalyses the first step in the serine biosynthesis pathway, and breast cancer cells with high PHGDH expression have increased serine synthesis flux. Suppression of PHGDH in cell lines with elevated PHGDH expression, but not in those without, causes a strong decrease in cell proliferation and a reduction in serine synthesis. We find that PHGDH suppression does not affect intracellular serine levels, but causes a drop in the levels of a-ketoglutarate, another output of the pathway and a tricarboxylic acid (TCA) cycle intermediate. In cells with high PHGDH expression, the serine synthesis pathway contributes approximately 50% of the total anaplerotic flux of glutamine into the TCA cycle. These results reveal that certain breast cancers are dependent on increased serine pathway flux caused by PHGDH overexpression and demonstrate the utility of in vivo negative-selection RNAi screens for finding potential anticancer targets.
Cancer cells adapt their metabolic processes to drive macromolecular biosynthesis for rapid cell growth and proliferation 1, 2 . RNA interference (RNAi)-based loss-of-function screening has proven powerful for the identification of new and interesting cancer targets, and recent studies have used this technology in vivo to identify novel tumour suppressor genes 3 . Here we developed a method for identifying novel cancer targets via negative-selection RNAi screening using a human breast cancer xenograft model at an orthotopic site in the mouse. Using this method, we screened a set of metabolic genes associated with aggressive breast cancer and stemness to identify those required for in vivo tumorigenesis. Among the genes identified, phosphoglycerate dehydrogenase (PHGDH) is in a genomic region of recurrent copy number gain in breast cancer and PHGDH protein levels are elevated in 70% of oestrogen receptor (ER)-negative breast cancers. PHGDH catalyses the first step in the serine biosynthesis pathway, and breast cancer cells with high PHGDH expression have increased serine synthesis flux. Suppression of PHGDH in cell lines with elevated PHGDH expression, but not in those without, causes a strong decrease in cell proliferation and a reduction in serine synthesis. We find that PHGDH suppression does not affect intracellular serine levels, but causes a drop in the levels of a-ketoglutarate, another output of the pathway and a tricarboxylic acid (TCA) cycle intermediate. In cells with high PHGDH expression, the serine synthesis pathway contributes approximately 50% of the total anaplerotic flux of glutamine into the TCA cycle. These results reveal that certain breast cancers are dependent on increased serine pathway flux caused by PHGDH overexpression and demonstrate the utility of in vivo negative-selection RNAi screens for finding potential anticancer targets.
As a starting point for identifying metabolic genes required for tumorigenesis, we cross-referenced maps of metabolic pathways with the KEGG database to compile a comprehensive list of 2,752 genes encoding all known human metabolic enzymes and transporters (Supplementary Table 1 ). Public oncogenomic data were analysed to score genes based on three properties: (1) higher expression in tumours versus normal tissues; (2) high expression in aggressive breast cancer; or (3) association with the stem-cell state (Fig. 1a) . Genes scoring in two of these three categories as well as those at the top of each category were selected to define a high-priority set of 133 metabolic enzyme and transporter genes (Supplementary Table 2 ). We assembled lentiviral short hairpin RNA (shRNA) vectors targeting these genes (median 5 shRNAs per gene) and used them to generate two libraries of shRNAexpressing lentiviruses, one containing 235 distinct shRNAs (targeting transporters and control genes) and the other 516 distinct shRNAs (targeting metabolic enzymes and control genes) 4 .
To identify genes that may be essential for tumorigenesis, the libraries were screened for shRNAs that become depleted during breast tumour formation in mice. Human MCF10DCIS.com cells 5 were chosen for the screens because, of several breast cancer lines examined, these were capable of forming tumours upon injection of the fewest number of cells. One and a half million MCF10DCIS.com cells were infected with each library so that each cell carried one viral integrant, and a Enzymes  CTPS  GAPDH  GLS2  GMPS  NUDT5  PHGDH  PLA2G7  PYCR1  SEPHS1  SOD2  TALDO1  TPI1   SLC15A1  SLC16A3  TTYH3 ,500-1,000 cells per shRNA (100,000-1,000,000 cells total) were injected into mouse mammary fat pads at two sites per animal (Supplementary Discussion). Twenty-eight days later orthotopic tumours were harvested and massively parallel DNA sequencing was used to determine the abundance of each shRNA in genomic DNA from tumours and initially injected cells (Fig. 1b) . shRNA abundances correlated well between replicate tumours (Fig. 1c) and 5 or 12 tumours per library were analysed to identify shRNAs that became significantly depleted during tumour formation. Sixteen genes were designated hits in the screen, with at least 75% of the shRNAs targeting these genes scoring ( Fig. 1d and Supplementary Table 3) . Several genes previously shown to have important roles in cancer emerged as hits, including the mitochondrial ATP transporter VDAC1; the lactic acid transporter SLC16A3; and the nucleotide synthesis genes GMPS and CTPS. The hit list also includes genes involved in the control of oxidative stress (SOD2, GLS2, SEPHS1), the pentose phosphate pathway (TALDO1), glycolysis (GAPDH, TPI1), and in the proline (PYCR1) and serine (PHGDH) biosynthetic pathways. An analogous pooled screen carried out in MCF10DCIS.com cells grown in culture rather than in tumour xenografts revealed that of 20 genes that scored in the in vitro screen, 10 also scored in the in vivo screen ( Supplementary Fig. 2a , Supplementary Table 3 and Supplementary Discussion). Interestingly, AK2, which encodes an adenylate kinase that generates ADP from ATP and AMP, was required for in vitro but not in vivo growth ( Supplementary Fig. 2b ).
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Hit genes
For five hit genes (PHGDH, GMPS, SLC16A3, PYCR1 and VDAC1), two scoring shRNAs were tested for their effects on tumour formation. Each of these shRNAs suppressed expression of their targets in MCF10DCIS.com cells and reduced tumour-forming capacity.
( Fig. 1e and Supplementary Fig. 2c ). For reasons discussed later, PHGDH was of particular interest. The three shRNAs that scored in the in vivo screen also decreased PHGDH protein expression, and two shRNAs of differing knockdown efficacies inhibited tumour growth, consistent with their capacity to suppress PHGDH expression (Fig. 1e) . Moreover, tumours derived from cells that in culture had confirmed reductions in PHGDH levels had, in immunohistochemical (Supplementary Fig. 3a ) and immunoblotting assays ( Supplementary  Fig. 3b ), PHGDH staining or levels similar to control tumours, suggesting that tumorigenesis selected for cells that lost shRNA-mediated PHGDH suppression.
To prioritize genes for follow-up studies we consulted a recently available analysis of copy number alterations across cancer genomes 6 . This analysis showed that PHGDH exists in a region of chromosome 1p commonly amplified in breast cancer and melanoma (Fig. 2a) , as well as in several other cancer types (not shown). In total, 18% of patientderived breast cancer cell lines and 6% of primary tumours have amplifications in PHGDH. In the data sets examined, none of the other hit genes are in genomic regions of focal and recurrent copy number gain.
Our meta-analysis for genes associated with aggressive breast cancer is corroborated by a previous study that found elevated PHGDH messenger RNA levels in breast cancers that are ER negative, of the basal type, and associated with poor 5-year survival 7 . We confirmed these associations in distinct gene expression data sets (Fig. 2b) and additionally found that PHGDH is elevated in ER-negative breast cancer relative to normal breast tissue (Fig. 2b) . Of all the genes identified as hits in our screen, PHGDH has the most significantly elevated expression in ER-negative breast cancer ( Supplementary Fig. 4 
LETTER RESEARCH
immunohistochemical assay for PHGDH, we found that PHGDH protein levels correlate significantly with ER-negative status (Fig. 2c) . In total, compared to ER-positive breast tumours, ,68% and ,70% of ER-negative breast tumours have elevations of PHGDH at the mRNA and protein levels, respectively (Fig. 2b, c and Supplementary Methods). ER-negative breast cancer comprises approximately 20-25% of all breast cancer cases, but as many as 50% of all breast cancer deaths within 5 years of diagnosis 8 , underscoring the importance of identifying additional drug targets for this class of breast cancer.
Across a set of breast cancer lines, four lines with PHGDH amplifications had 8-12-fold higher PHGDH protein expression compared to non-transformed MCF-10A and ER-positive MCF-7-cell lines, which do not have PHGDH amplifications (Fig. 2d) . Mechanisms other than gene copy number increases must also exist for boosting PHGDH expression because PHGDH protein levels were also elevated in two ER-negative cell lines (MT-3, Hs578T) lacking the PHGDH amplification (Fig. 2e) . This is consistent with the finding that PHGDH expression is upregulated at the mRNA and protein level in a higher fraction of ER-negative breast cancers than the fraction exhibiting amplification at the DNA level. Interestingly, PHGDH is also expressed fourfold more in the MCF10DCIS.com cells used in the in vivo screen than in two parental lines (MCF-10A and MCF10AT) that exhibit no or lower tumorigenicity 9 ( Fig. 2f ). PHGDH encodes 3-phosphoglycerate dehydrogenase, the first enzyme branching from glycolysis in the three-step serine biosynthetic pathway 10 ( Fig. 3a) . PHGDH uses NAD as a cofactor to oxidize the glycolytic intermediate 3-phosphoglycerate into phosphohydroxypyruvate 11, 12 , which subsequent enzymes in the pathway convert into serine via transamination (PSAT1) and phosphate ester hydrolysis (PSPH) reactions 10 ( Fig. 3a) . Serine is essential for synthesis of proteins and other biomolecules needed for cell proliferation, including nucleotides, phosphatidyl-serine and sphingosine ( Supplementary Fig. 1 ). Classic studies show elevated serine biosynthetic activity, as determined by enzyme assays, in rat tumour lysates 10, 13 , and suggest that PSPH is the rate-limiting enzyme of this pathway in the liver 14 . Interestingly, we find that numerous genes that are expected to promote serine biosynthesis or are involved in the subsequent metabolism of serine for biosynthesis are elevated in ER-negative breast cancer ( Supplementary Fig. 5 ), demonstrating that PHGDH elevation occurs in the context of upregulation of a broader pathway.
To understand the metabolic consequences of increased PHGDH expression we used metabolite profiling and serine synthesis pathway flux analysis to examine breast cancer cells with and without PHGDH amplifications. We found that cells with PHGDH amplifications (BT-20, MDA-MB-468 and HCC70), had increased flux through the serine synthesis pathway compared to those without PHGDH amplifications (MDA-MB-231, MCF7 and MCFC10A) ( Fig. 3b and Supplementary  Fig. 6a ). Cells with elevated PHGDH and high pathway flux were capable of robust proliferation in medium lacking serine, whereas in cells with low levels of PHGDH, the deprivation of serine caused a significant blunting or even cessation of proliferation ( Supplementary  Fig. 6b ).
PHGDH is required for the increased serine pathway flux of cells with elevated PHGDH because RNAi-mediated PHGDH suppression significantly reduced flux in MDA-MB-468 and BT-20 cells (Fig. 3c) . Conversely, in MCF-10A human mammary cells engineered to overexpress PHGDH, serine pathway flux increased to levels similar to those in MDA-MB-468, BT-20 and HCC70 cells (Fig. 3d) . Furthermore, MCF-10A cells overexpressing PHGDH had increased proliferation in the absence of serine, indicating that PHGDH overexpression is sufficient to drive flux through the pathway (Supplementary Fig. 6c ). Interestingly, overexpression of PSPH, considered the rate-limiting serine biosynthetic enzyme in the liver, did not increase pathway flux in MCF-10A cells (Fig. 3d) . The observation that PSPH is rate limiting 
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in the liver whereas PHGDH is rate limiting in MCF-10A cells can be reconciled by the observation that serine levels in the liver (2 mM) are well above the concentration at which PSPH is feedback-inhibited by serine (500 mM), but low in cell lines in culture (,100 mM), a concentration at which PSPH should be active 14 . These data demonstrate that PHGDH is a key enzyme controlling flux through the serine biosynthetic pathway in cancer cells.
We next asked if cells with an increase in PHGDH expression require it for cell proliferation and survival. In cell lines with elevated PHGDH expression (BT-20, MDA-MB-468, HCC70, Hs578T and MT-3), but not without (MDA-MB-231 and MCF-7), RNAi-mediated suppression of PHGDH caused a marked decrease in cell number (Fig. 3e, f and Supplementary Fig. 6d ) and cell death (Fig. 3g and Supplementary Fig. 6e ) in the absence of apoptotic markers (Supplementary Fig. 6f ). This sensitivity to PHGDH suppression was observed both in cells with PHGDH amplifications (BT-20, MDA-MB-468 and HCC70) and in those with high PHGDH expression but lacking PHGDH amplification (MT-3 and Hs578T). Consistent with flux through the serine synthesis pathway being important in cells with high PHGDH expression, suppression of the other two enzymes in the pathway (PSAT1 and PSPH) inhibited the proliferation of MDA-MB-468 and BT-20, but not MCF-7, cells ( Supplementary  Fig. 6g ). Moreover, inhibition of PSPH inhibited tumour formation by MCF10DCIS.com cells (Supplementary Fig. 6h ). Therefore, elevated PHGDH expression defines a set of breast cancer cell lines with increased serine pathway flux that are dependent upon PHGDH, PSAT1 and PSPH for proliferation. This finding suggests that many ER-negative breast cancers that express PHGDH at high levels (,70% of all ER-negative disease in our data set; Fig. 2c ) may be sensitive to inhibitors of the serine synthesis pathway.
To investigate whether PHGDH suppression can affect the growth of established tumours, we generated an inducible shRNA 15 that, upon doxycycline treatment, reduced PHGDH protein levels in MDA-MB-468 cells (Fig. 3h) . MDA-MB-468 cells transduced with this shRNA were allowed to form murine mammary fat pad tumours for 25 days before introduction of doxycycline in a subset of mice (Fig. 3h) . Compared to control mice, those given doxycycline exhibited substantially reduced tumour growth, whereas tumours made from cells transduced with a control inducible shRNA grew equally well in the presence or absence of doxycycline (Fig. 3h) . These results indicate that PHGDH suppression can adversely affect growth in existing tumours (Supplementary Discussion).
Serine is a central metabolite for biosynthetic reactions, and we find that overexpression of PHGDH contributes significantly to biosynthetic flux to serine. However, PHGDH suppression inhibited proliferation even in cells growing in media containing normal levels of extracellular serine (Fig. 3f) , and supplementation with additional serine or a cell-permeable methyl-serine-ester did not blunt the effects of PHGDH suppression (Fig. 4a, b) . Intracellular and extracellular serine are in equilibrium ( Supplementary Fig. 7a ), and import of extracellular serine was not defective in the cell lines studied (Supplementary Fig. 7b ). These findings suggest that serine production may not be the only important role of PHGDH in cell lines with high PHGDH expression. We considered three hypotheses to explain our observations: (1) serine produced via the PHGDH pathway is used in a different manner than exogenous serine; (2) suppression of PHGDH adversely affects glycolysis; or (3) the PHGDH, PSAT1 and PSPH reactions produce metabolites besides serine that are also critical for cell proliferation. The first hypothesis was deemed unlikely because serine synthesized intracellularly is in equilibrium with extracellular serine (Supplementary Fig. 7a ). The second hypothesis was also unlikely because PHGDH suppression did not affect glucose uptake or lactate production ( Supplementary Fig. 7c) .
To pursue the third hypothesis, we considered which additional metabolites the serine synthesis pathway might produce in significant levels in cells with high PHGDH expression. The serine pathway produces equimolar amounts of serine and a-ketoglutarate (aKG; Supplementary Fig. 1 ). Proliferating cells use intermediates of the TCA cycle, such as aKG, as biosynthetic precursors, and upregulate anaplerotic reactions that drive glutamine-derived carbon into the TCA cycle, counterbalancing biosynthetic efflux 16 (Supplementary Discussion). We hypothesized that in cells with high PHGDH expression, the PSAT1 reaction might contribute a significant fraction of glutamate to aKG flux. If true, the serine biosynthesis pathway would have an important role in TCA anaplerosis of glutamine-derived carbon. Consistent with this possibility, suppression of PHGDH in MDA-MB-468 cells caused a large reduction in the levels of aKG ( Fig. 4c and Supplementary Fig. 7d ). In fact, of the major metabolites measured, aKG was the one with the most significant and largest change upon PHGDH suppression, whereas serine levels were not significantly changed (Supplementary Fig. 8 ). PHGDH suppression also caused a significant reduction in other TCA components (Fig. 4d and Supplementary Fig. 8 ). Like suppression of PHGDH, suppression of PSAT1 also caused a significant reduction in serine pathway flux and aKG levels ( Fig. 4c and Supplementary Fig. 7d, e) . Furthermore, labelling studies using U- 13 C-glutamine revealed that the absolute flux from glutamine to aKG and other TCA intermediates was significantly reduced in cells with RNAi-mediated suppression of PHGDH or 
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PSAT1 (Fig. 4e and Supplementary Fig. 9a, b) . These data indicate that in cell lines with high PHGDH expression, the serine synthesis pathway is responsible for approximately 50% of the net conversion of glutamate to aKG and that suppression of PHGDH results in a significant loss of TCA intermediate flux and steady-state levels of TCA intermediates ( Fig. 4f and Supplementary Fig. 9a, b) . Furthermore, labelling studies using U- 13 C-glucose in cell lines with PHGDH amplification (MDA-MB-468) and without (MDA-MB-231) revealed that in cells with high PHGDH expression, flux through the serine biosynthesis pathway shunts 8-9% of the glycolytic flux towards serine production, compared to 1-2% in the cell line with low PHGDH expression ( Fig. 4f and Supplementary Fig. 9a) . Therefore, increased flux through the serine biosynthesis pathway has a major impact on aKG production, but a smaller effect on glycolysis or serine availability in these cells (Supplementary Discussion). In contrast, another prominent aKG-producing transaminase, alanine aminotransferase, does not contribute significantly to aKG production in PHGDH-amplified cells (Supplementary Fig. 10 ).
We find that PHGDH expression is a critical part of a cellular program promoting serine pathway flux (Supplementary Fig. 5 ) and is responsible for a considerable portion of anaplerosis of glutamate into the TCA cycle as aKG ( Supplementary Fig. 1 ). As ,70% of ER-negative breast cancers exhibit elevated PHGDH (Fig. 2c) , our work suggests that targeting the serine synthesis pathway may be therapeutically valuable in breast cancers with elevated PHGDH expression or PHGDH amplifications (Supplementary Discussion). Lastly, we anticipate that the screening approach described here may be applicable to other cancer types or gene sets, enabling the identification of novel cancer targets directly in an in vivo context.
METHODS SUMMARY
To undertake negative-selection RNAi screening in solid tumours, pools of MCF10DCIS.com cells expressing an shRNA library were injected into the fourth mammary fat pad of immunocompromised mice and allowed to form tumours. Abundances of shRNAs in the tumours were determined using massively parallel sequencing and compared to shRNA abundance in the injected cells. Genes targeted by shRNAs that were significantly depleted during tumour growth were considered hits and prioritized by analysing gene copy number data from human tumours and cancer cell lines. Lentiviral shRNAs were used to suppress PHGDH expression in breast cancer cell lines with and without PHGDH genomic amplification. Serine synthesis pathway activity and anaplerosis were measured via flux analyses using isotopically labelled molecules.
METHODS
Materials. Materials were obtained from the following sources: antibodies to PHGDH (HPA021241) and PSPH (HPA020376) from Sigma; an antibody against PYCR1 (13108-1-AP) from Proteintech; an antibody against GMPS (A302-417A) from Bethyl Labs; an antibody against VDAC1 (ab16814) from Abcam; antibodies to RPS6 (2217), PARP (9532) and Caspase-3 (9662) from Cell Signaling Technologies; an antibody against PSAT1 (H00029968-A01) from Novus Biologicals; an antibody against SLC16A3 (AB3316P) from Millipore; and HRPconjugated anti-mouse, anti-rabbit secondary antibodies from Santa-Cruz Biotechnology; lactate dehydrogenase from Roche (10127230001); lactic acid from Acros; RPMI-1640 media, 3-bromopyruvate and glycine/hydrazine solution (G5418) from Sigma; a- . The TRC numbers for the shRNAs used are: GFP, TRCN0000072186; PHGDH_1, TRCN0000221861; PHGDH_2, TRCN0000221865; PSPH_1, TRCN0000002796; PSPH_2, TRCN0000315168; PSAT1_1, TRCN0000035266; PSAT1_2, TRCN0000035268; SLC16A3_1, TRCN0000038477; SLC16A3_2, TRCN0000038478; VDAC1_1, TRCN0000029126; VDAC1_2, TRCN0000029127; GMPS_1, TRCN0000045938; GMPS_2, TRCN0000045941; PYCR1_1, TRCN0000038979; PYCR1_2, TRCN0000038980. The TRC website is http://www.broadinstitute.org/ rnai/trc/lib. The doxycycline-inducible shRNA vector used was previously described 15 .
Cell culture. MDA-MB-468, MDA-MB-231, BT-20, HCC1599, HCC70, DU4475, ZR-75-30, MT-3, Hs578T and MCF-7 were cultured in RPMI supplemented with 10% IFS and penicillin/streptomycin. MCF-10A and MCF10AT1 cells were cultured as described previously 17 . MCF10DCIS.com cells were cultured in 50:50 DMEM and F12 media with 5% horse serum and penicillin/streptomycin. Compilation of metabolic gene list. A list of all human metabolic enzymes and small molecule transporters was generated by cross-referencing maps of metabolic pathways (Roche) with the KEGG database (http://www.genome.jp/kegg/kegg1. html). NCBI resources including Entrez Gene (http://www.ncbi.nlm.nih.gov/ gene) and the available literature were used to identify known or putative gene function and to identify functional homologues. A protein was considered a metabolic enzyme if it modified a small molecule to generate another small molecule. Proteins which modified polymerized DNA or RNA or which modified proteins were excluded. In cases where an enzyme could modify both a small molecule and a macromolecule, we favoured a more liberal criterion of inclusion. A protein was considered a small molecule transporter if it formed a pore or channel through which a small molecule could traverse a lipid bilayer. Accessory or regulatory subunits of larger protein complexes were generally excluded. Meta-analysis of oncogenomic data. To generate a cancer-relevant 'high priority' subset of metabolic genes (out of the 2,752 genes we classified as metabolic enzymes or small molecule transporters), we first identified those genes whose expression is significantly associated with the transformed state, advanced breast cancer, or stemness. Genes associated with the transformed state were obtained by analysing 36 gene expression studies deposited in Oncomine 18 that profiled normal human tissue and primary tumours derived from them. The gene expression profiles in each study were classified as normal or tumour and for each group the log 2 median centred intensity for each gene was determined. A P value associated with the significance of the difference between the two groups was calculated with the Student's t-test. After ranking the genes based on the P values, the top 10% of the genes with lowest P values were selected from each of the 36 studies. From these genes we identified those that are in the top 10% of the most upregulated metabolic genes across the all 36 studies at a P value ,0.05. Genes associated with aggressive breast cancer were obtained by analysing 15 gene expression studies from Oncomine that profiled ER 2 versus ER 1 tumours, grade 3 versus grade 1 or 2 tumours, tumours of basal versus epithelial morphology, or tumours from patients who failed to survive after 5 years of follow-up versus those who did survive at 5 years. The 15 studies were analysed as above to identify those genes that are in the top 10% of the most upregulated metabolic genes across the studies at a P value ,0.05. To identify genes associated with stemness, we analysed gene expression studies comparing differentiated cells with stem cells 19 , chromatin immunoprecipitation studies of stem-cell-associated transcription factors 20, 21 , and a previous meta-analysis of stemness-associated genes 22 . Genes were considered to be associated with stemness if their average expression was greater than fourfold upregulated in the stem versus differentiated cells profiles analysed previously 19 or if their promoters were bound by at least two stem-cell-specific transcription factors (Oct4, Nanog, Sox2, Tcf3, Dax1, Nac1 or Klf4) in both studies analysed. To generate the final high priority set of 133 genes that was screened (Supplementary Table 2 ), three categories of genes were selected: (1) genes scoring in all three analyses; (2) the most significantly scoring ,5% of genes in any one category; and (3) the most significantly scoring ,10% of genes in any two categories. Identification of cell lines for use in pooled screening. To undertake negativeselection RNAi screening, a cell line that could form a tumour upon injection of the minimum number of cells was identified. To accomplish this, 11 breast cell lines that previously identified as capable of forming tumours were selected and 100,000 cells from each were injected into the fourth murine mammary fat pad. The cell lines tested included BT-20, BT-474, MCF10DCIS.com, HBL100, MCF7, MDA-MB-157, MDA-MB-231, MDA-MB-361, MDA-MB-453, T47D and ZR-75-1. After one month, tumours were scored by size and number scoring per site, and tumours or injection sites were analysed histologically to verify the presence of a tumour, or to identify microscopic tumours. In the timeframe of the experiment, MDA-MB-231, MDA-MB-361, MDA-MB-453, MCF7 and T47D cells formed microscopic tumours, whereas MCF10DCIS.com formed large tumours and ZR-75-1 formed small macroscopic tumours reproducibly. MCF10DCIS.com cells were then injected into murine mammary fat pads at 100,000, 10,000, 1,000 and 100 cells per site. All of these injections were capable of forming tumours, and tumour size correlated with the number of cells injected. The MCF10DCIS.com cell line was finally shown to be suitable for in vivo screening upon performing a screen using 180 shRNAs and demonstrating that nearly all of the shRNAs introduced initially could be recovered from the tumour and that replicate tumours exhibited significant correlation in those shRNAs over-or underrepresented compared to the injected pool. These experiments should not be construed to indicate that the excluded cell lines would not also be suitable for in vivo screening, as they were not tested using an shRNA pool. Pooled shRNA screening. pLKO.1 lentiviral plasmids encoding shRNAs targeting the 133 transporters and metabolic enzymes listed in Supplementary Table 2 were obtained and combined to generate two plasmid pools. One contained the plasmids encoding shRNAs targeting all 47 transporters and another the plasmids encoding shRNAs targeting all 86 metabolic enzymes as well as control shRNAs designed not to target any gene. These plasmid pools were used to generate lentivirus-containing supernatants as described 23 . MCF10DCIS.com cells were infected with the pooled virus so as to ensure that each cell contained only one viral integrant. Cells were selected for 3 days with 0.5 mg ml 21 puromycin. For the in vivo screen, cells were injected in 33% growth factor reduced matrigel into the fourth mammary fat pad of NOD.CB17 Scid/J mice (Jackson Labs) at 100,000 to 1,000,000 cells per injection site and tumours were harvested 4 weeks after implantation. For the in vitro screen, cells were plated in replicates of four at 1,000,000 per 10-cm plate and split at 1:8 once confluent (every 3-5 days) for 25-28 days. Genomic DNA was isolated from tumours or cells by digestion with proteinase K followed by isopropanol precipitation. To amplify the shRNAs encoded in the genomic DNA, PCR was performed for 33 cycles at an annealing temperature of 66 uC using 2-6 mg of genomic DNA, the primer pair indicated below, and DNA polymerase. So that PCR products obtained from many different tumours could be sequenced together, forward primers containing unique 2-nucleotide barcodes were used (see below). After purification, the PCR products from each tumour were quantified by ethidium bromide staining after gel electrophoresis, pooled at equal proportions, and analysed by high-throughput sequencing (Illumina) using the primer indicated below. shRNAs from up to 16 genomic DNA samples were sequenced together. Sequencing reads were deconvoluted using GNU Octave software by segregating the sequencing data by barcode and matching the shRNA stem sequences to those expected to be present in the shRNA pool, allowing for mismatches of up to 3 nucleotides. The Log 2 values reported are the average Log base 2 of the fold change in the abundance of each shRNA in the pre-injection cells compared to tumours, for n 5 5 tumours for the transporter pool and n 5 12 tumours for the metabolic enzyme pool, or to cells at day 25-28 for n 5 4 in vitro cultures. P values were determined by two-sided homoscedastic unpaired t-test comparing each shRNA to a basket of negativecontrol shRNAs contained within the shRNA pools. Individual shRNAs were identified as scoring in the screens using a P value cutoff of 0.05 and Log 2 foldchange cutoff of 21. Genes for which .75% of the shRNAs targeting the gene scored were considered hits. Individual shRNAs were considered to be differentially required in vitro versus in vivo using a P-value cutoff of 0.05 by a two-sided homoscedastic unpaired t-test comparing the in vitro and in vivo shRNA Log 2 fold change scores. For the transporter pool screen, this required normalization to the median of the two distributions. shRNAs present at less than 30 reads in the preinjection cell sample were eliminated from further analysis.
Follow-up tumour growth studies of individual genes followed a similar timeline as above, except that during PHGDH and PSPH follow-up (Fig. 1e and LETTER RESEARCH
